Chimerix

News Releases

2011

Chimerix to Present at Cowen and Company 31st Annual Health Care Conference

   

DURHAM, NC, March 1, 2011 - Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics to address life-threatening diseases, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present at the Cowen and Company 31st Annual… > Read More

Chimerix Awarded BARDA Contract for Advanced Development of CMX001 as Medical Countermeasure Against Smallpox

   

RESEARCH TRIANGLE PARK, NC, February 16, 2011 - Chimerix, Inc., a pharmaceutical company developing orally available antiviral therapeutics, today announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) for the advanced development… > Read More

Disseminated AdV Infection Eradicated in a Pediatric Hematopoietic Stem Cell Transplantation Recipient who Received Chimerix's CMX001

   

— Emergency IND Case Report of Broad-Spectrum Antiviral CMX001 Published in Journal of Clinical Virology

DURHAM, NC, February 24, 2011 – Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today… > Read More

Chimerix to Present at the Citi 2011 Global Health Care Conference

   

DURHAM, NC, February 24, 2011 - Chimerix, Inc., a pharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present at the Citi 2011 Global Health… > Read More

Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157

   

- Financing Reflects Significant Clinical Progress and Positive Data in Lead Programs

RESEARCH TRIANGLE PARK, NC, February 14, 2011 – Chimerix, Inc., a pharmaceutical company developing orally-available broad spectrum antiviral therapeutics, today announced the… > Read More

Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Life-Threatening or Serious dsDNA Viral Infections

   

- New Expanded Access Study Builds on CMX001 Emergency IND and Clinical Experience

RESEARCH TRIANGLE PARK, NC, JANUARY 7, 2011 - Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced that patient enrollment has… > Read More

2010

Chimerix's Antiviral CMX157 Demonstrates Positive Phase 1 Results with Favorable Pharmacokinetics, Safety & Toler...

   

- Exhibits Potent In Vitro Activity Against XMRV and Highly Resistant HIV

DURHAM, NC, DECEMBER 13, 2010 - Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced first-in-human Phase 1 clinical trial results for… > Read More

Chimerix's Lead Antiviral CMX001 Administered in Combination with Recombinant Human Interleukin-7 in a Patient with PML

   

— Emergency IND Case Study of Broad-Spectrum Antiviral CMX001 and Cytheris’ CYT107 Published in Journal of Antimicrobial Chemotherapy —

RESEARCH TRIANGLE PARK, NC, DECEMBER 1, 2010 - Chimerix, Inc., a pharmaceutical company developing orally-available antiviral… > Read More

Chimerix Broad-Spectrum Antiviral CMX001 Shown in Animal Model to be a Potent Inhibitor of Herpes Simplex Viruses

   

- Preclinical Data Demonstrating CMX001 Penetration of Blood-Brain Barrier and Superiority to Acyclovir Against HSV Infection Published in

- The Journal of Infectious Diseases

RESEARCH TRIANGLE PARK, NC, NOVEMBER 22, 2010 - Chimerix, Inc., a pharmaceutical… > Read More

Chimerix to Present at Piper Jaffray 22nd Annual Health Care Conference

   

Research Triangle Park, NC, November 19, 2010 – Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present at the… > Read More

 < 1 2 3 4 >  Last ›